

# SEQUENCE LISTING

<110> Novo Nordisk A/S

<120> SPONTANEOUSLY DISPERSIBLE PRECONCENTRATES INCLUDING  
A PEPTIDE DRUG IN A SOLID OR SEMISOLID CARRIER

<130> 7713.504-WO

<160> 4

<170> PatentIn version 3.4

<210> 1

<211> 31

<212> PRT

<213> homo sapiens

<400> 1

His	Ala	Glu	Gly	Thr	Phe	Thr	Ser	Asp	Val	Ser	Ser	Tyr	Leu	Glu	Gly
1				5					10					15	

Gln	Ala	Ala	Lys	Glu	Phe	Ile	Ala	Trp	Leu	Val	Lys	Gly	Arg	Gly
			20					25					30	

<210> 2

<211> 40

<212> PRT

<213> Heloderma suspectum

<220>

<221> MISC\_FEATURE

<222> (40)..(40)

<223> Xaa is NH2

<400> 2

His	Gly	Glu	Gly	Thr	Phe	Thr	Ser	Asp	Leu	Ser	Lys	Gln	Met	Glu	Glu
1				5					10					15	

Glu	Ala	Val	Arg	Leu	Phe	Ile	Glu	Trp	Leu	Lys	Asn	Gly	Gly	Pro	Ser
			20					25					30		

Ser	Gly	Ala	Pro	Pro	Pro	Ser	Xaa
			35				40

<210> 3

<211> 40

<212> PRT

<213> Artificial

<220>

<223> Derivative of Exendin-4

<220>

<221> MISC\_FEATURE

<222> (20)..(20)

<223> Xaa is N-epsilon(17-carboxyheptadecanoic acid)Lys

<220>

<221> MISC\_FEATURE

<222> (40)..(40)

<223> Xaa is NH2

<400> 3

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu  
1 5 10 15

Glu Ala Val Xaa Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser  
20 25 30

Ser Gly Ala Pro Pro Pro Ser Xaa  
35 40

<210> 4

<211> 40

<212> PRT

<213> Artificial

<220>

<223> Derivative of Exendin-4

<220>

<221> MISC\_FEATURE

<222> (32)..(32)

<223> Xaa is N-epsilon-(17-carboxy-heptadecanoyl)Lys

<220>

<221> MISC\_FEATURE

<222> (40)..(40)

<223> Xaa is NH2

<400> 4

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu  
1 5 10 15

Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Xaa  
20 25 30

Ser Gly Ala Pro Pro Pro Ser Xaa  
35 40